Table 1 Study cohort.
From: Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults
| Â | B-ALL | T-lineage ALL | ||
|---|---|---|---|---|
TP53-mutant (n = 125) | TP53 wild-type (n = 388) | TP53-mutant (n = 14) | TP53 wild-type (n = 90) | |
Age, years (range) | 62 (18–86) | 46 (18–88) | 42 (20–77) | 37 (18–88) |
Age groups (years) | ||||
 18–39 | 23 (18) | 152 (39) | 7 (50) | 48 (53) |
 40–60 | 31 (25) | 128 (33) | 5 (36) | 26 (29) |
 >60 | 71 (57) | 108 (28) | 2 (14) | 16 (18) |
Sex, n (%) | ||||
 Female | 58 (46) | 198 (51) | 6 (43) | 29 (32) |
 Male | 67 (54) | 190 (49) | 8 (57) | 61 (68) |
T-lineage subtype | ||||
 ETP | NA | NA | 1 (7) | 24 (27) |
 Pre-T |  |  | 13 (93) | 66 (73) |
Year of diagnosis | ||||
 2010–2014 | 27 (22) | 46 (12) | 2 (14) | 6 (7) |
 2015–2019 | 53 (42) | 200 (51) | 7 (50) | 49 (54) |
 2020–2024 | 45 (36) | 142 (37) | 5 (36) | 35 (39) |
Ethnicity | ||||
 White | 63 (50) | 149 (38) | 7 (50) | 34 (38) |
 Hispanic | 10 (8) | 55 (14) | 0 | 5 (6) |
 Black | 10 (8) | 26 (7) | 4 (29) | 13 (14) |
 Asian | 1 (1) | 8 (2) | 0 | 4 (4) |
 Unknown | 41 (33) | 150 (39) | 3 (21) | 34 (38) |
First-line therapy | ||||
 Hyper-CVAD | 34 (27) | 104 (27) | 5 (36) | 15 (17) |
 Pediatric | 31 (25) | 131 (34) | 6 (43) | 55 (61) |
 Low intensity chemotherapy | 28 (22) | 89 (23) | 1 (7) | 4 (4) |
 Antibody | 7 (6) | 10 (2) | 0 | 0 |
 Hyper-CVD + venetoclax | 5 (4) | 9 (2) | 0 | 3 (3) |
 Unknown | 20 (16) | 45 (12) | 2 (14) | 13 (14) |
Allogeneic HCT, n (%) | 21/84 (25) | 60/249 (24) | 2/8 (25) | 14/57 (25) |
